Medigene AG (MDGEF)
USD 2.59
(0.0%)
USD 2.59
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -16.17 Million EUR | -94.2% |
| 2022 | -8.33 Million EUR | 16.56% |
| 2021 | -9.98 Million EUR | 65.43% |
| 2020 | -28.87 Million EUR | -44.65% |
| 2019 | -19.96 Million EUR | 5.95% |
| 2018 | -21.22 Million EUR | -56.38% |
| 2017 | -13.57 Million EUR | -42.99% |
| 2016 | -9.49 Million EUR | 26.98% |
| 2015 | -12.99 Million EUR | -125.79% |
| 2014 | -5.75 Million EUR | 44.01% |
| 2013 | -10.28 Million EUR | 30.89% |
| 2012 | -14.87 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.08 Million EUR | 0.0% |
| 2023 Q4 | -4.6 Million EUR | 0.0% |
| 2023 Q3 | -4.6 Million EUR | -13.44% |
| 2023 FY | -16.17 Million EUR | -94.2% |
| 2023 Q1 | -3.48 Million EUR | 68.67% |
| 2023 Q2 | -4.05 Million EUR | -16.44% |
| 2022 Q2 | -2.39 Million EUR | -134.37% |
| 2022 Q3 | -11.12 Million EUR | -365.07% |
| 2022 Q4 | -11.12 Million EUR | 0.0% |
| 2022 FY | -8.33 Million EUR | 16.56% |
| 2022 Q1 | 6.95 Million EUR | 261.17% |
| 2021 FY | -9.98 Million EUR | 65.43% |
| 2021 Q3 | -2.15 Million EUR | 61.89% |
| 2021 Q4 | -4.31 Million EUR | -100.0% |
| 2021 Q1 | -2.83 Million EUR | 82.67% |
| 2021 Q2 | -5.66 Million EUR | -100.0% |
| 2020 Q2 | -12.53 Million EUR | -100.0% |
| 2020 Q1 | -6.26 Million EUR | -21710.34% |
| 2020 Q4 | -16.34 Million EUR | -100.0% |
| 2020 Q3 | -8.17 Million EUR | 34.81% |
| 2020 FY | -28.87 Million EUR | -44.65% |
| 2019 Q1 | -5.67 Million EUR | 29.7% |
| 2019 Q4 | 29 Thousand EUR | 100.51% |
| 2019 Q2 | -3.93 Million EUR | 30.63% |
| 2019 FY | -19.96 Million EUR | 5.95% |
| 2019 Q3 | -5.7 Million EUR | -44.89% |
| 2018 Q2 | -3.68 Million EUR | 11.66% |
| 2018 Q3 | -5.3 Million EUR | -44.05% |
| 2018 FY | -21.22 Million EUR | -56.38% |
| 2018 Q4 | -8.07 Million EUR | -52.17% |
| 2018 Q1 | -4.16 Million EUR | 21.34% |
| 2017 FY | -13.57 Million EUR | -42.99% |
| 2017 Q4 | -5.29 Million EUR | -64.57% |
| 2017 Q3 | -3.22 Million EUR | 15.11% |
| 2017 Q2 | -3.79 Million EUR | -3.13% |
| 2017 Q1 | -3.67 Million EUR | 2.36% |
| 2016 Q2 | 986 Thousand EUR | 171.09% |
| 2016 Q3 | -5.32 Million EUR | -639.96% |
| 2016 Q1 | -1.38 Million EUR | 43.27% |
| 2016 FY | -9.49 Million EUR | 26.98% |
| 2016 Q4 | -3.76 Million EUR | 29.24% |
| 2015 Q2 | -2.44 Million EUR | 33.52% |
| 2015 FY | -12.99 Million EUR | -125.79% |
| 2015 Q4 | -2.44 Million EUR | 44.93% |
| 2015 Q3 | -4.44 Million EUR | -81.89% |
| 2015 Q1 | -3.67 Million EUR | -3149.56% |
| 2014 Q3 | -2.8 Million EUR | -251.82% |
| 2014 Q4 | -113 Thousand EUR | 95.97% |
| 2014 Q2 | -797 Thousand EUR | 61.01% |
| 2014 Q1 | -2.04 Million EUR | 19.97% |
| 2014 FY | -5.75 Million EUR | 44.01% |
| 2013 Q4 | -2.55 Million EUR | -23.26% |
| 2013 Q3 | -2.07 Million EUR | 13.09% |
| 2013 Q2 | -2.38 Million EUR | 27.16% |
| 2013 FY | -10.28 Million EUR | 30.89% |
| 2013 Q1 | -3.27 Million EUR | 66.27% |
| 2012 Q3 | -2.39 Million EUR | 0.0% |
| 2012 FY | -14.87 Million EUR | 0.0% |
| 2012 Q4 | -9.7 Million EUR | -305.47% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioxytran, Inc. | -4.28 Million USD | -277.967% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 78.42% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -5816.928% |
| SQZ Biotechnologies Company | -79.46 Million USD | 79.642% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -459.294% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 130.535% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 124.837% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -788.588% |
| Marizyme, Inc. | -65.34 Million USD | 75.244% |
| Genus plc | 7.9 Million USD | 304.772% |
| Pharming Group N.V. | -10.54 Million USD | -53.366% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -645.548% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -336.01% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -82.915% |
| ContraFect Corporation | -65.15 Million USD | 75.171% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -836.464% |
| IMV Inc. | -36.48 Million USD | 55.662% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -100.715% |
| ONE Bio Corp. | 8.67 Million USD | 286.444% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 68.705% |
| Mesoblast Limited | -87.95 Million USD | 81.608% |
| MultiCell Technologies, Inc. | -380.07 USD | -4256221.204% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -333.351% |
| Genscript Biotech Corporation | -95.47 Million USD | 83.057% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2458.005% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -579.458% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -145.996% |
| Biomind Labs Inc. | -1.21 Million USD | -1232.187% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -421.541% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -104.692% |
| Skye Bioscience, Inc. | -37.64 Million USD | 57.027% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -729.909% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -48.525% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -107919.498% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -231.085% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -131.668% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -1.925% |
| Accustem Sciences Inc. | -3.74 Million USD | -331.799% |
| EV Biologics, Inc. | -1.26 Million USD | -1176.661% |
| Q BioMed Inc. | -2.05 Million USD | -688.317% |
| GB Sciences, Inc. | -1.36 Million USD | -1088.02% |
| Alpha Cognition Inc. | -13.77 Million USD | -17.458% |
| CSL Limited | 2.64 Billion USD | 100.612% |
| Agentix Corp. | -1.37 Million USD | -1077.185% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 72.914% |
| Enzolytics Inc. | -2.17 Million USD | -643.144% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -3.61 Million USD | -348.116% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -410.084% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -178.087% |
| argenx SE | -295.05 Million USD | 94.517% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 74.158% |
| HST Global, Inc. | -146.21 Thousand USD | -10964.223% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 16607.143% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -821.887% |
| Halberd Corporation | -79.67 Thousand USD | -20203.479% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 333.617% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -434.576% |
| Zenith Capital Corp. | -10.59 Million USD | -52.671% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -307.174% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -290.189% |
| AVAX Technologies, Inc. | -6.41 Million USD | -152.228% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -26665.117% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -706.787% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -69502.444% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | -239.198% |
| Helix BioMedix, Inc. | -1.05 Million USD | -1431.83% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -323.593% |
| Kadimastem Ltd | -3.3 Million USD | -389.116% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | -90.699% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -3565.187% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1111.369% |
| LadRx Corporation | 400.44 Thousand USD | 4139.776% |
| Cell Source, Inc. | -5.32 Million USD | -204.01% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -3793.578% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1680.545% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1680.545% |
| Affymax, Inc. | -14.42 Million USD | -12.153% |
| Mobile Lads Corp. | -2.26 Million USD | -614.755% |
| Itoco Inc. | -1.86 Million USD | -765.545% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -264.139% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -869.263% |
| International Stem Cell Corporation | -131 Thousand USD | -12248.855% |
| CytoDyn Inc. | -49.84 Million USD | 67.543% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -20368.665% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -6991.226% |
| Qrons Inc. | -789.34 Thousand USD | -1949.416% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -1618.163% |
| SYBLEU INC | -180.3 Thousand USD | -8872.069% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -674.879% |
| Rebus Holdings, Inc. | -1.02 Million USD | -1485.98% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -903.077% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -29707.267% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -539.345% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 66.348% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -665.232% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -1971.619% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -410.638% |
| Neutra Corp. | -233.46 Thousand USD | -6829.09% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 20.275% |
| PureTech Health plc | -65.69 Million USD | 75.376% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 23.932% |
| IXICO plc | -1.17 Million USD | -1273.26% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -62.96% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 71.683% |
| CSL Limited | 2.64 Billion USD | 100.612% |
| Cellectis S.A. | -103.17 Million USD | 84.321% |